Copyright
©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 109989
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.109989
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.109989
Table 1 Overview of included systematic reviews
| Ref. | Year | No. of studies | Patients (RLR, LLR, OLR) | Study designs | Key focus |
| Safiejko et al[6] | 2024 | 8 | 3210 (530, 2680, N/A) | 1 prospective, 6 retrospective, 1 randomized | RLR vs LLR intraoperative/postoperative |
| Machairas et al[7] | 2021 | 9 | 29 (29, N/A, N/A) | Case series | Simultaneous robotic resections |
| Mkabaah et al[9] | 2025 | 13 | 6582 (268, 3333, 2981) | 2 RCTs, 1 prospective, 10 retrospectives | Comparative outcomes of RLR, LLR, OLR |
| Ho et al[12] | 2013 | 19 | 217 (142, 43, 32) | 10 case series, 2 comparative, 7 case reports | Early RLR adoption and complications |
| McGuirk et al[13] | 2021 | 8 | 28 (28, N/A, N/A) | Case series | Technical feasibility of RLR |
Table 2 Conversion rates
| Ref. | Year | RLR conversion rate | LLR conversion rate | OLR conversion rate | Statistical comparison |
| Safiejko et al[6] | 2024 | 6.7% (NR) | 12.4% (NR) | NR | LLR vs RLR: OR = 2.18, 95%CI: 1.46-3.24 |
| Machairas et al[7] | 2021 | 0% (0/29) | NR | NR | NR |
| Mkabaah et al[9] | 2025 | 4.7% (10/214) | 10.4% (328/3166) | NR | LLR vs RLR: OR = 27.50, 95%CI: 7.73-97.48 |
| Ho et al[12]1 | 2013 | 4.6% (10/217) | NR | NR | NR |
| McGuirk et al[13] | 2021 | 0% (0/28) | NR | NR | NR |
Table 3 Perioperative morbidity and mortality
| Ref. | 30-day mortality | 90-day mortality | Postoperative complications |
| Safiejko et al[6] | |||
| RLR | 0.5% (2/372); RLR vs LLR: OR = 1.23, 95%CI: 0.32-4.83 | 0.0% (0/178); RLR vs LLR: OR = 1.78, 95%CI: 0.23-14.03 | 21.9% (106/482); RLR vs LLR: OR = 1.04, 95%CI: 0.81-1.32 |
| LLR | 0.7% (13/1931) | 1.3% (10/789) | 22.4% (404/1806) |
| Machairas et al[7] | 0% (0/29) | 0% (0/29) | 37.9% (11/29) |
| Mkabaah et al[9] | |||
| RLR | 0.7% (2/268); RLR vs OLR: OR = 1.24, 95%CI: 0.24-6.36 | 0.6% (1/179); RLR vs OLR: OR = 0.45, 95%CI: 0.07-3.03 | 23.6% (45/191); RLR vs OLR: OR = 0.52, 95%CI: 0.32-0.86 |
| LLR | 0.3% (5/1530); LLR vs OLR: OR = 1.01, 95%CI: 0.29-3.58 | 0.3% (1/292); LLR vs OLR: OR = 0.64, 95%CI: 0.08-5.24 | 16.6% (113/678); LLR vs OLR: OR = 0.50, 95%CI: 0.37-0.68 |
| OLR | 0.7% (6/862) | 1.4% (4/296) | 26.4% (262/992) |
| Ho et al[12] | 0% (0/217) | 0% (0/217) | 20.3% (48/236) |
| McGuirk et al[13] | 0% (0/28) | 2.8% (1/28) | 28.6% (8/28) |
Table 4 Oncological outcomes
| Ref. | R0 resection rate | 1-year OS | 3-year OS | 5-year OS | Key oncological findings |
| Safiejko et al[6] | NR | 81.8% (RLR) vs 91.8% (LLR) | 47.7% (RLR) vs 65.9% (LLR) | NR | Trend favoring LLR (NS) |
| Machairas et al[7] | 100% (29/29) | NR | NR | 75.2% (single study) | All R0 resections |
| Mkabaah et al[9] | |||||
| RLR | 82.1% (202/246) | 100% (12/12) | 41.7% (5/12) | NR | No significant differences between approaches |
| LLR | 84.6% (2501/2957) | 93.0% (213/229) | 69.4% (159/229) | 53.1% (191/360) | |
| OLR | 87.7% (2277/2597) | 96.4% (321/333) | 69.3% (231/333) | 60.8% (477/785) | |
| Ho et al[12] | NR | NR | NR | NR | Mixed malignancies included |
| McGuirk et al[13] | 100% (28/28) | NR | NR | NR | Margin status reported for all cases1 |
Table 5 Operative and postoperative metrics
| Ref. | Operating time (min) | Blood loss (mL) | Hospital stay (d) | Key findings |
| Safiejko et al[6] | 247.9 (RLR) vs 272.9 (LLR) | 190.8 (RLR) vs 294.3 (LLR) | 5.8 (RLR) vs 5.6 (LLR) | RLR reduced blood loss vs LLR (P < 0.001) |
| Machairas et al[7] | 399.5 (median) | 274 (median) | 7 (median) | Simultaneous resections |
| Mkabaah et al[9] | ||||
| RLR | 304.1 | 266.8 | 6.2 | RLR reduced blood loss vs OLR (P < 0.001) |
| LLR | 191.8 | 283.9 | 6.7 | |
| OLR | 204.3 | 413.8 | 12.9 | |
| Ho et al12] | 200-507 (range) | 50-660 (range) | 5.5-11.7 (range) | Early RLR experience |
| McGuirk et al[13] | 420.3 | 275.6 | 8.6 | Single-arm (no comparator) |
Table 6 Methodological quality (Assessment of Multiple Systematic Reviews 2 assessment)
| Ref. | Confidence rating | Key strengths | Key limitations |
| Safiejko et al[6] | Moderate | Direct RLR vs LLR comparison | Retrospective dominance, no RCTs |
| Machairas et al[7] | Low | Focus on SRAR | Small cohort, no comparator group |
| Mkabaah et al[9] | High | Large sample, subgroup analyses | Heterogeneity in study designs |
| Ho et al[12] | Low | Early RLR adoption data | Outdated, mixed malignancies included |
| McGuirk et al[13] | Low | Detailed technical insights | Small sample, case series bias |
- Citation: Ardila CM, Zuluaga-Gómez M, González-Arroyave D. Robotic liver surgery for metastatic disease: A review of safety, feasibility, and outcomes. World J Gastrointest Surg 2025; 17(11): 109989
- URL: https://www.wjgnet.com/1948-9366/full/v17/i11/109989.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i11.109989
